Article

Dr. Robert Dubois On Promoting Comparative Results Vs. Methodology

Robert W. Dubois, MD, PhD, Chief Science Officer, National Pharmaceutical Council, discusses the different circumstances in the level of restrictions and evidence regarding comparative effectiveness research. In addition, Dr. Dubois asks whether the standards around safety differ from those around efficacy.

Related Videos
Mikkael Sekeres, MD
Clayton Irvine, PharmD, MBA, MS.
Debra Patt, MD, PhD, MBA, MPH
Carrie Kozlowski, OT, MBA, Upfront Healthcare
Debra Patt, MD, PhD, MBA, MPH
Sarah Anderson, oncology strategy lead director, Novotech
Gladys Antelo-Allen
Related Content
Jeff Stark, MD, UCB
February 6th 2025

Dr Jeff Stark: New Bimzelx Dose Offers Simplicity and Choice

Maggie L. Shaw Jeff Stark, MD
On October 14, 2024, the FDA approved a 320-mg single dose of bimekizumab-bkzx (Bimzelx; UCB) in a 2-mL prefilled syringe and autoinjector; both forms are now commercially available in the US.
Managed Care Cast Logo
February 4th 2025

Politics vs Science: The Future of US Public Health

Maggie L. Shaw Perry N. Halkitis, PhD, MS, MPH
On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Travis Brewer, Texas Oncology
January 30th 2025

Balancing Cost and Quality in Oncology: A Value-Based Care Perspective

Skylar Jeremias Travis Broome, MPH, MBA
Travis Brewer, vice president of payer and public health strategy/relations at Texas Oncology, shared that value-based oncology care can achieve both cost efficiency and high-quality outcomes through integrated multidisciplinary teams, flexible payment models, and targeted treatment approaches.
managed care cast logo
January 28th 2025

The Evolving Annual Wellness Visit

Laura Joszt, MA Christopher Wheelock, MD
The annual wellness visit is beneficial for patients, providers, and payers with an emphasis on preventive care for early intervention.
Kirollos Hanna, PharmD
January 29th 2025

Embracing EOM, Enhancing Collaboration and Cost Management: Dr Kirollos Hanna

Kyle Munz Kirollos Hanna, PharmD
The design of the Enhancing Oncology Model (EOM) was a perfect fit for Minnesota Oncology.
Kirollos Hanna, PharmD
January 28th 2025

Balancing Longevity, Quality, and Cost in Oncology Care

Kyle Munz Kirollos Hanna, PharmD
Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, director of pharmacy at Minnesota Oncology, discusses how the prospect of patient longevity, amidst advancing therapeutics, factors into oncology care.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo